Search Results - "Zeitoun, Jean‐David"

Refine Results
  1. 1

    Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010 by Downing, Nicholas S, Shah, Nilay D, Aminawung, Jenerius A, Pease, Alison M, Zeitoun, Jean-David, Krumholz, Harlan M, Ross, Joseph S

    “…IMPORTANCE: Postmarket safety events of novel pharmaceuticals and biologics occur when new safety risks are identified after initial regulatory approval of…”
    Get full text
    Journal Article
  2. 2

    Assessing a New Prescreening Score for the Simplified Evaluation of the Clinical Quality and Relevance of eHealth Apps: Instrument Validation Study by Wagneur, Nicolas, Callier, Patrick, Zeitoun, Jean-David, Silber, Denise, Sabatier, Remi, Denis, Fabrice

    Published in Journal of medical Internet research (05-07-2022)
    “…Background In 2020, more than 250 eHealth solutions were added to app stores each day, or 90,000 in the year; however, the vast majority of these solutions…”
    Get full text
    Journal Article
  3. 3

    Long‐term efficacy of fibrin glue injection for perianal fistulas in patients with Crohn's disease by Vidon, Mathias, Munoz‐Bongrand, Nicolas, Lambert, Jérôme, Maggiori, Léon, Zeitoun, JeanDavid, Corte, Hélène, Panis, Yves, Seksik, Philippe, Treton, Xavier, Abramowitz, Laurent, Allez, Matthieu, Gornet, Jean‐Marc

    Published in Colorectal disease (01-04-2021)
    “…Aim The treatment of perianal fistulas in Crohn's disease remains challenging. Fibrin glue injection has previously shown short‐term efficacy in a randomized…”
    Get full text
    Journal Article
  4. 4

    Functional digestive symptoms and quality of life in patients with Ehlers-Danlos syndromes: results of a national cohort study on 134 patients by Zeitoun, Jean-David, Lefèvre, Jérémie H, de Parades, Vincent, Séjourné, César, Sobhani, Iradj, Coffin, Benoît, Hamonet, Claude

    Published in PloS one (22-11-2013)
    “…Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders. Gastrointestinal manifestations in EDS have been described…”
    Get full text
    Journal Article
  5. 5

    Reciprocal association between voting and the epidemic spread of COVID-19: observational and dynamic modeling study by Zeitoun, Jean-David, Faron, Matthieu, Manternach, Sylvain, Fourquet, Jérôme, Lavielle, Marc, Lefèvre, Jérémie H

    Published in European journal of public health (01-12-2021)
    “…Abstract Background Whether voting is a risk factor for epidemic spread is unknown. Reciprocally, whether an epidemic can deter citizens from voting has not…”
    Get full text
    Journal Article
  6. 6

    Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing by Vivot, Alexandre, Boutron, Isabelle, Béraud-Chaulet, Geoffroy, Zeitoun, Jean-David, Ravaud, Philippe, Porcher, Raphaël

    Published in Scientific reports (31-07-2017)
    “…For oncology drugs that were approved by the US Food and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the use of…”
    Get full text
    Journal Article
  7. 7

    Predicting the propagation of COVID-19 at an international scale: extension of an SIR model by Lavielle, Marc, Faron, Matthieu, Lefevre, Jérémie H, Zeitoun, Jean-David

    Published in BMJ open (25-05-2021)
    “…ObjectivesSeveral epidemiological models have been published to forecast the spread of the COVID-19 pandemic, yet many of them have proven inaccurate for…”
    Get full text
    Journal Article
  8. 8

    Post‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional study by Zeitoun, JeanDavid, Baron, Gabriel, Vivot, Alexandre, Atal, Ignacio, Downing, Nicholas S, Ross, Joseph S, Ravaud, Philippe

    Published in International journal of cancer (15-01-2018)
    “…Post‐marketing research in oncology has rarely been described. We aimed to characterize post‐marketing trials for a consistent set of anticancer agents over a…”
    Get full text
    Journal Article
  9. 9

    Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis by Zeitoun, JeanDavid, Ross, Joseph S., Atal, Ignacio, Vivot, Alexandre, Downing, Nicholas S., Baron, Gabriel, Ravaud, Philippe

    Published in Clinical pharmacology and therapeutics (01-11-2018)
    “…We examined whether drug‐related characteristics—conditions, development, manufacturers, revenues—were associated with postmarketing research in terms of the…”
    Get full text
    Journal Article
  10. 10

    Health as an independent predictor of the 2017 French presidential voting behaviour: a cross-sectional analysis by Zeitoun, Jean-David, Faron, Matthieu, de Vaugrigneuse, Sophie, Lefèvre, Jérémie H

    Published in BMC public health (06-11-2019)
    “…It has been suggested that poor health has influenced vote for Brexit and the US presidential election. No such research has been published regarding the 2017…”
    Get full text
    Journal Article
  11. 11

    Automatic classification of registered clinical trials towards the Global Burden of Diseases taxonomy of diseases and injuries by Atal, Ignacio, Zeitoun, Jean-David, Névéol, Aurélie, Ravaud, Philippe, Porcher, Raphaël, Trinquart, Ludovic

    Published in BMC bioinformatics (22-09-2016)
    “…Clinical trial registries may allow for producing a global mapping of health research. However, health conditions are not described with standardized…”
    Get full text
    Journal Article
  12. 12

    Patients' Perceptions and Preferences Regarding Two Different Forms of Methotrexate Autoinjectors for Moderate to Severe Rheumatoid Arthritis: A European Crossover Survey by Zeitoun, Jean-David, Morvan, Yves

    Published in Patient preference and adherence (01-01-2020)
    “…Treatment adherence is crucial in patients with rheumatoid arthritis (RA). The device used by the patients for self-injections may influence adherence to…”
    Get full text
    Journal Article
  13. 13

    Readmissions After Surgery: A French Nationwide Cross-Sectional Study of 1,686,602 Procedures Performed in 2010 by Lefèvre, Jérémie H., Reboul-Marty, Jeanne, de Vaugrigneuse, Sophie, Zeitoun, Jean-David

    Published in World journal of surgery (2017)
    “…Background Surgical readmissions have been extensively studied in North America, but very few data from other countries are available. We aimed to describe…”
    Get full text
    Journal Article
  14. 14

    Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018 by Zeitoun, Jean-David, Duclos, Antoine, de Parades, Vincent, Lefèvre, Jérémie H.

    Published in Human vaccines & immunotherapeutics (01-12-2020)
    “…While national authorities recommended and provided reimbursement for men who have sex with men under 27 in 2016 and 2017, respectively, we aimed to…”
    Get full text
    Journal Article
  15. 15

    Frequency and risk factors of severe postoperative bleeding after proctological surgery: a retrospective case-control study by Taieb, Sarah, Atienza, Patrick, Zeitoun, Jean-David, Taouk, Milad, Bourguignon, Josée, Thomas, Christian, Rabahi, Nabila, Dahlouk, Saliha, Lesage, Anne-Carole, Lobo, David, Etienney, Isabelle

    Published in Annals of coloproctology (01-10-2022)
    “…Purpose: The aim of this study was to assess frequency and risk factors of severe bleeding after proctological surgery requiring hemostatic surgery observed…”
    Get full text
    Journal Article
  16. 16

    Regulatory review time and post‐market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional study by Zeitoun, JeanDavid, Lefèvre, Jérémie H., Downing, Nicholas S., Bergeron, Henri, Ross, Joseph S.

    Published in British journal of clinical pharmacology (01-10-2015)
    “…Aims Regulatory review time has been associated with post‐market medication safety issues in the United States. Our objective was to evaluate whether…”
    Get full text
    Journal Article
  17. 17

    Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study by Zeitoun, Jean-David, Ross, Joseph S, Atal, Ignacio, Vivot, Alexandre, Downing, Nicholas S, Baron, Gabriel, Ravaud, Philippe

    Published in BMJ open (01-12-2017)
    “…ObjectivesTo characterise postmarketing studies for drugs that were newly approved by the US Food and Drug Administration and the European Medicines…”
    Get full text
    Journal Article
  18. 18

    Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison by Zeitoun, Jean-David, Lefèvre, Jérémie H, Downing, Nicholas, Bergeron, Henri, Ross, Joseph S

    Published in PloS one (21-10-2014)
    “…The European Medicines Agency (EMA) and national regulators share the responsibility to communicate to healthcare providers postmarketing safety events but…”
    Get full text
    Journal Article
  19. 19

    Long-term Outcome of a Fissurectomy: A Prospective Single-Arm Study of 50 Operations out of 349 Initial Patients by Zeitoun, Jean-David, Blanchard, Pierre, Fathallah, Nadia, Benfredj, Paul, Lemarchand, Nicolas, de Parades, Vincent

    Published in Annals of coloproctology (01-04-2018)
    “…The surgical standard of care for patients with chronic anal fissure is still disputed. We aimed to assess the natural course of idiopathic anal fissure and…”
    Get full text
    Journal Article
  20. 20

    Brain injury unmasking Ehlers-Danlos syndromes after trauma: the fiber print by Hamonet, Claude, Frédy, Daniel, Lefèvre, Jérémie H, Bourgeois-Gironde, Sacha, Zeitoun, Jean-David

    Published in Orphanet journal of rare diseases (22-04-2016)
    “…The role of physical trauma in the onset of symptoms in Ehlers-Danlos syndrome (EDS) has never been characterized. We sought to search and describe brain…”
    Get full text
    Journal Article